RAPT Therapeutics (NASDAQ: RAPT) grants director 4,956 RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RAPT Therapeutics reported an equity grant to director Scott Braunstein. On 01/30/2026, he received 4,956 shares of common stock at a price of $0 per share as a stock-based award, leaving him with 4,956 shares beneficially owned directly.
The award represents the annual grant of restricted stock units (RSUs) under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Braunstein Scott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,956 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 4,956 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did RAPT (RAPT) report for Scott Braunstein?
RAPT reported that director Scott Braunstein received 4,956 shares of common stock on 01/30/2026. The shares came through an annual restricted stock unit grant under the non-employee director compensation policy and were reported at a price of $0 per share.
What is the vesting schedule for Scott Braunstein’s RSUs at RAPT (RAPT)?
The restricted stock units granted to Scott Braunstein fully vest on the first anniversary of the 01/30/2026 grant date. Once vested, each RSU represents a contingent right to receive one share of RAPT common stock, aligning his compensation with long-term shareholder value.
What policy governs Scott Braunstein’s stock grant at RAPT (RAPT)?
Scott Braunstein’s stock grant is made under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. This policy provides annual restricted stock unit awards to non-employee directors, which fully vest on the first anniversary of the grant date and convert into common stock.